Novartis Promotion: Novartis acquires Kresbdiagnosechemikalien-Geschäft and Siemens Healthineers | 25.08.24

The German Medizintechnik group of Siemens Healthineers has made a unifying effect on the general molecular imaging for Fluorine-18-Positron-Emissions-Tomography (PET), a new dissemination on the Anfrage of AWP with scattered media reports.

Novartis has been very knowledgeable about the future results of AAA. “The planted Veräusserung follows a strategic Beurteilung, which the Schluss Kam, the Wachstum of the Molecular-Imaging-Geschäfts is best under the Führung a spezialisierten Diagnostic-Aktionärs unterstützt kann”, so the Sprecherin. The deal was stopped through the efforts of all regulators in the four quarters closed.

You can read the “Financial Times” online with a report about the transaction. Blatt has taken the turnover from the sale for more than 200 million euros. Novartis itself no longer uses the Verkaufspreis.

Siemens Healthineers was acquired by the Siemens parent company in 2017. The company is looking at the expansion of Europe for its large PET radiopharmaceutical business offered in the US in the overarching news. The Novartis speech therapy organization has helped Siemens Healthineers become the transaction partner for the radioligand therapy business of Novartis.

TV/

LONDON (awp international)